Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR1 | P11362 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.38 |
| ▸ | ABL1 | P00519 | 2/20 | 0.37 |
| ▸ | BCR | P11274 | 2/20 | 0.37 |
| ▸ | TNF | P01375 | 3/20 | 0.34 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.34 |
| ▸ | DUT | P33316 | 1/20 | 0.33 |
| ▸ | ACACB | O00763 | 1/20 | 0.33 |
| ▸ | HDAC6 | Q9UBN7 | 2/20 | 0.32 |
| ▸ | FPR2 | P25090 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4014331 | 0.85 | HDAC6 (0.41) | FGFR1FGFR4SLC22A12NOTUMHDAC6 | |
| SCHEMBL21137545 | 0.81 | NOTUM (0.43) | FGFR1FGFR4SLC22A12ABL1BCR | |
| SCHEMBL24669199 | 0.81 | DRD2 (0.43) | FGFR1FGFR4SLC22A12 | |
| SCHEMBL16363382 | 0.79 | FGFR1 (0.43) | FGFR1FGFR4SLC22A12ABL1BCR | |
| SCHEMBL28112933 | 0.78 | NOTUM (0.43) | FGFR1FGFR4SLC22A12ABL1BCR | |
| SCHEMBL3401964 | 0.77 | TNF (0.45) | FGFR1FGFR4SLC22A12ABL1BCR | |
| SCHEMBL31330492 | 0.76 | SLC22A12 (0.41) | FGFR1FGFR4SLC22A12ABL1BCR | |
| SCHEMBL27849552 | 0.75 | KDM4E (0.44) | FGFR1FGFR4SLC22A12ABL1BCR | |
| SCHEMBL1897615 | 0.74 | SLC22A12 (0.41) | FGFR1FGFR4SLC22A12ABL1BCR | |
| SCHEMBL31720885 | 0.74 | SLC22A12 (0.41) | FGFR1FGFR4SLC22A12ABL1BCR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11970506-B2 | Bioactive molecule conjugate, preparation method and use thereof | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2024-04-30 | — | — | US | disclosed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2023-11-09 | — | — | US | disclosed |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2021-04-08 | — | — | US | disclosed |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. (CN) | 2020-11-05 | — | — | US | disclosed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
| EP-3725798-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (CN) | 2020-10-21 | — | — | EP | disclosed |
| WO-2019114666-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | 四川科伦博泰生物医药股份有限公司 | 2019-06-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230357259-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | FGFR1 2055/4885FGFR4 1994/4885SLC22A12 1445/4885 |
| US-11970506-B2 | Bioactive molecule conjugate, preparation method and use thereof | PIGO, RHOA, GUSB | FGFR1 424/4885FGFR4 1195/4885SLC22A12 3508/4885 |
| US-20200347075-A1 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | FGFR1 2055/4885FGFR4 1994/4885SLC22A12 1445/4885 |
| US-20210101906-A2 | BIOACTIVE CONJUGATE, PREPARATION METHOD THEREFOR AND USE THEREOF | DOCK11, PAICS, RHOA | FGFR1 2055/4885FGFR4 1994/4885SLC22A12 1445/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.